TECHNOLOGY

Provenance’s technologies harness the immune system to recognize and fight disease at its source, the recently identified cancer stem cell.

Cancer stem cells are believed to originate through mutation of normal cells and are then nurtured in a protective stem cell niche. They eventually develop into cancer as we know it through cellular differentiation. Traditional cancer therapies target the progeny of cancer stem cells but not the source, since these rare cells are naturally resistant to chemotherapy and radiation. Provenance Biopharmaceuticals’ technologies target cancer at its source by inducing the body’s immune system to kill these highly tumorigenic cells, and develop an immune memory against them.

 

Selected Publications

Craig B. Davis, Stephen D. Gillies, Immunocytokines: amplification of anti-cancer immunity. Cancer Immunol Immunother 52: 297-308 (2003)

Stephen D. Gillies, Yan Lan, Steven Williams, Frank Carr, Stephen Forman, Andrew Raubitschek and Kin Ming Lo, An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood 105: 3972-3978 (2005)

Harjeet Singh, Lisa Marie Serrano, Timothy Pfeiffer, Simon Olivares, George McNamara, David D. Smith, Zaid Al-Kadhimi, Stephen J. Forman, Stephen D. Gillies, Michael C. Jensen, David Colcher, Andrew Raubitschek, and Laurence J.N. Cooper, Combining Adoptive Cellular and Immunocytokine Therapies to Improve Treatment of B-Lineage Malignancy. Cancer Res 67(6):2872-80 (2007)